Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus supernatant is a cell-free preparation containing the secreted metabolites, proteins, and signaling molecules produced by *Lactobacillus* species during fermentation. In research targeting systemic lupus erythematosus (SLE), supernatants derived from a consortium of five strains—*Lactobacillus reuteri, Lactobacillus oris, Lactobacillus johnsonii, Lactobacillus gasseri,* and *Lactobacillus rhamnosus*—have been evaluated for their ability to modulate the immune system. While live bacterial mixtures of these strains have demonstrated therapeutic potential by increasing regulatory T cells and restoring the balance of T helper 17 cells in lupus-prone mouse models, the supernatant alone failed to significantly attenuate disease symptoms in some studies. This suggests that the therapeutic efficacy of *Lactobacillus*-based microbiome therapies may depend on live bacterial interactions, structural components of the cell wall, or specific community-driven metabolic processes rather than secreted factors alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus supernatant.